Xtx Topco LTD Wave Life Sciences Ltd. Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Xtx Topco LTD holds 15,334 shares of WVE stock, worth $200,722. This represents 0.01% of its overall portfolio holdings.

Number of Shares

15,334

Holding current value

$200,722

% of portfolio

0.01%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$5.12 - $9.01 $78,510 - $138,159	15,334 New	15,334 $125,000
Q1 2024 May 13, 2024	BUY	$3.54 - $6.84 $165,802 - $320,365	46,837 New	46,837 $288,000
Q3 2023 Nov 13, 2023	SELL	$3.56 - $5.75 $103,884 - $167,790	-29,181 Reduced 47.48%	32,280 $185,000
Q2 2023 Aug 14, 2023	BUY	$3.51 - $4.69 $215,728 - $288,252	61,461 New	61,461 $223,000
Q3 2022 Nov 14, 2022	BUY	$2.37 - $4.28 $42 - $77	18 Added 0.16%	11,335 $41,000
Q2 2022 Aug 15, 2022	BUY	$1.23 - $3.25 $13,919 - $36,780	11,317 New	11,317 $37,000
Q1 2022 May 13, 2022	SELL	$2.0 - $3.28 $31,306 - $51,341	-15,653 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$3.14 - $5.15 $49,150 - $80,612	15,653 New	15,653 $49,000

Others Institutions Holding WVE

# of Institutions

164

Shares Held

117M

Call Options Held

148K

Put Options Held

109K

Ra Capital Management, L.P. Boston, MA

18.2M
Shares

$238 Million
2.08% of portfolio
Lee Ainslie Maverick Capital LTD | Dallas, Tx

10M
Shares

$132 Million
1.71% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

9.7M
Shares

$127 Million
0.15% of portfolio
Black Rock Inc. New York, NY

6.74M
Shares

$88.2 Million
0.0% of portfolio
M28 Capital Management LP Stamford, CT

6.16M
Shares

$80.7 Million
48.05% of portfolio

View Full List

About Wave Life Sciences Ltd.

Ticker WVE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,820,096
Market Cap $1.14B
Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...

More about WVE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account